Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.
Soligenix, Inc. (NASDAQ: SNGX) is repeatedly described in its public communications as a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. News about SNGX often centers on progress across its two segments, Specialized BioTherapeutics and Public Health Solutions, and provides updates on clinical trials, regulatory designations, advisory boards and financing activities.
In the Specialized BioTherapeutics segment, recent press releases highlight the ongoing confirmatory Phase 3 FLASH2 study of HyBryte™ (SGX301, synthetic hypericin sodium) for cutaneous T-cell lymphoma (CTCL), including enrollment milestones and interim safety reviews. Additional news covers Phase 2a clinical results for SGX302 in mild-to-moderate psoriasis, emphasizing improvements in standard psoriasis indices with synthetic hypericin-based photodynamic therapy, and publications and regulatory designations for SGX945 (dusquetide) in Behçet's Disease, including orphan drug designation from the FDA.
Coverage of Soligenix also includes updates on its innate defense regulator (IDR) technology platform, describing dusquetide’s role in modulating the innate immune response, and on its Public Health Solutions programs such as the RiVax® ricin toxin vaccine candidate, filovirus vaccines and CiVax™ for COVID-19, which use the ThermoVax® heat-stabilization platform and have received support from agencies like NIAID, DTRA and BARDA.
Investors following SNGX news can expect announcements about clinical trial milestones, peer-reviewed publications, FDA orphan and fast track designations, medical advisory board expansions in CTCL, as well as capital markets events such as public offerings and Nasdaq listing compliance updates. Bookmarking the SNGX news page on Stock Titan can help track these developments in one place as the company advances its rare-disease and biodefense pipeline.
Soligenix (NASDAQ:SNGX) has successfully closed its previously announced public offering, raising $7.5 million in gross proceeds. The offering consisted of 5,555,560 shares of common stock (or equivalents) and warrants at a combined price of $1.35 per share and accompanying warrant.
The warrants are immediately exercisable at $1.35 per share and will expire in five years. Additionally, certain existing warrants from May 2023, April 2024, and July 2024 will be amended to match the new $1.35 exercise price. The funding extends Soligenix's cash runway through 2026, supporting research, development, and commercialization activities.
Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, has announced the pricing of a $7.5 million public offering. The offering includes 5,555,560 shares of common stock (or equivalents) and warrants at a combined price of $1.35 per share and warrant.
The warrants will have an exercise price of $1.35, immediate exercisability, and a five-year expiration. Additionally, certain existing warrants from May 2023, April 2024, and July 2024 will be amended to match the new $1.35 exercise price. The offering is expected to close around September 29, 2025, with A.G.P./Alliance Global Partners serving as the sole placement agent.
Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, has appointed former White House Economic Adviser Dr. Tomas J. Philipson as Strategic Advisor. Dr. Philipson brings extensive experience in U.S. economic and healthcare policy, having served as vice chairman and acting chairman of the White House Council of Economic Advisers from 2017 to 2020.
Dr. Philipson's notable experience includes advisory roles at the FDA and CMS, and he currently serves as Managing Partner at MEDA Ventures. His appointment comes as Soligenix advances HyBryte™, its lead product candidate, through a confirmatory Phase 3 clinical trial, along with other fast-tracked rare disease pipeline programs.
Soligenix (Nasdaq: SNGX) announced the successful long-term stability testing of its ebolavirus vaccines using the ThermoVax® platform. The company demonstrated that both bivalent and trivalent vaccine formulations maintained their potency after two years of storage at temperatures up to 40°C (104°F).
In collaboration with the University of Hawaiʻi, the vaccines, which target Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus, showed significant stability advantages. The vaccines only require reconstitution with sterile water before use, eliminating complex cold-storage requirements typical of other vaccine technologies.
The research highlights the potential of Soligenix's ThermoVax® platform in developing thermostable vaccines that could improve global vaccination efforts, particularly in virus-endemic African regions and strategic national stockpiles.
Soligenix (Nasdaq: SNGX), a late-stage biopharmaceutical company specializing in rare disease treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's CEO, Christopher J. Schaber, Ph.D., will deliver a corporate presentation during the event scheduled for September 8-10, 2025.
The on-demand presentation will be available starting September 5th at 7:00 AM ET for registered attendees through the conference platform. Management will also conduct one-on-one meetings throughout the conference, with scheduling available through the conference platform.
Soligenix (NASDAQ:SNGX) has received FDA orphan drug designation for dusquetide (SGX945) for the treatment of Behçet's Disease, following promising Phase 2a clinical results. This designation provides seven years of market exclusivity upon FDA approval and various financial benefits including government grants, FDA fee waivers, and tax credits.
The treatment targets a rare disorder affecting up to 18,000 people in the U.S. and approximately 1 million worldwide. The Phase 2 proof-of-concept study demonstrated clinically meaningful improvements in patients with oral aphthous ulcers due to Behçet's Disease, addressing an significant unmet medical need in this chronic auto-immune condition.
Soligenix (NASDAQ:SNGX) reported its Q2 2025 financial results and recent accomplishments. The company posted a net loss of $2.7 million ($0.82 per share) compared to $1.6 million ($1.31 per share) in Q2 2024. The company held $5.1 million in cash as of June 30, 2025, plus $1.4 million received via ATM facility on July 1, providing runway through Q1 2026.
Key developments include completion of Phase 2a proof of concept study for SGX945 in Behçet's Disease, successful manufacturing transfer of synthetic hypericin to the US, and ongoing clinical trials. The company expects top-line results from Phase 2a psoriasis trial with SGX302 before year-end 2025, and anticipates Phase 3 HyBryte™ CTCL study results in 2026.
Soligenix (NASDAQ: SNGX) is advancing its HyBryte™ platform to address the growing need for effective treatments in cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer primarily affecting older adults. The company has successfully established U.S.-based manufacturing for HyBryte's active ingredient.
The development comes amid increasing healthcare challenges related to rare diseases, which affect over 30 million Americans. The initiative aligns with the "Make America Healthy Again" program, which aims to improve treatment access and accelerate medical innovation, particularly for an aging population facing complex healthcare needs and often experiencing diagnostic delays.
Soligenix (NASDAQ: SNGX) is advancing its HyBryte™ platform to address the growing need for treatments in rare diseases, specifically targeting cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting primarily older adults. The company has successfully established U.S.-based manufacturing for HyBryte's active ingredient.
This development aligns with healthcare initiatives aimed at improving treatment access and accelerating medical innovation, particularly relevant as over 30 million Americans live with rare diseases. The company's focus on CTCL represents a strategic move to address an underserved therapeutic area, especially significant given the aging American population and the challenges in diagnosing rare diseases in seniors.
Soligenix (NASDAQ: SNGX) has announced positive results from its Phase 2a clinical trial of SGX945 (dusquetide) for treating Behçet's Disease. The study demonstrated biological efficacy comparable to the approved drug apremilast (Otezla®), showing a 40% improvement in oral ulcers versus placebo after 4 weeks of treatment.
Key findings include sustained improvement even 4 weeks after treatment cessation, with 7 out of 8 patients reporting benefits. Unlike apremilast, which requires continuous administration and has side effects like diarrhea (41%), nausea (19%), and headache (14%), SGX945 showed no treatment-related adverse events. The company plans to reformulate SGX945 for subcutaneous home-based treatment and proceed with a placebo-controlled Phase 2 study.
FAQ
What is the current stock price of Soligenix (SNGX)?
What is the market cap of Soligenix (SNGX)?
